01 9Revlimid
02 3Revlimid
03 1Revlimid - BMS
04 1Revlimid - Celgene
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 12,106
2019 Revenue in Millions : 9,378
Growth (%) : 29
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 77
2020 Revenue in Millions : 52
Growth (%) : 48
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 12,821
2020 Revenue in Millions : 12,106
Growth (%) : 6
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 83
2021 Revenue in Millions : 77
Growth (%) : 8
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 9,978
2021 Revenue in Millions : 12,821
Growth (%) : -22
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 6,097
2022 Revenue in Millions : 9,978
Growth (%) : -39
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 82
2022 Revenue in Millions : 83
Growth (%) : -4
Main Therapeutic Indication : Blood Related Disorders
Currency : USD
2015 Revenue in Millions : 4,980
2014 Revenue in Millions : 5,801
Growth (%) : 16%
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 8,187
2016 Revenue in Millions : 6,974
Growth (%) : 17
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 6,974
2015 Revenue in Millions : 5,801
Growth (%) : 20
LOOKING FOR A SUPPLIER?